Received this email this morning; gives a look into BP:
Smoking Cessation Drugs:
World Market Prospects
2013-2023
Pharma report
Anti-smoking drug revenues will expand - you see what's most likely to succeed
How much revenue can medicines to treat smoking generate? Visiongain's updated report gives you predictions, helping you stay ahead. There you see financial results, R&D trends, opportunities, and commercial potential.
In that new study you discover forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess technologies, competition, and expected developments for treating tobacco addiction. Find prospects there.
Read on to explore those products and see what their future market could be worth.
Forecasts from 2013-2023 and other analyses to help you find opportunities
Besides revenue forecasting to 2023, our analysis shows recent results, growth rates, and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). You also get 60 tables, 36 charts, and four interviews.
Discover what's happening in that industry, using our report to find data you need
In that study you hear what's happening for smoking medications, learning where needs and money exist. Try our report now, seeing how you and your organisation can gain.
Avoid falling behind, missing business or losing influence. Instead, discover information you need to stay ahead. Our work explains, helping your research, analyses, and decisions.
The following sections, then, show what you get in that new investigation.
Sales predictions for the world market and submarkets
Discover in our report overall world revenue to 2023 for smoking-cessation drugs. You also find individual revenue forecasts for therapeutic submarkets at world level:
• Over-the-counter medicines (OTC)
• Prescription drugs (Rx)
• Nicotine replacement therapies (NRT)
• Nicotine receptor partial agonists (NRPA)
• Antidepressants.
How will sales of those therapies expand? Which classes of treatments will generate most money? There you assess prospects for revenue growth, seeing where you can benefit.
You also discover sales predictions by agent, seeing how they can succeed.
Revenue predictions for top products - see what's possible
How will those anti-addiction medicines perform to 2023 at world level? Our report forecasts individual revenues of six leading brands:
• Champix/Chantix
• NiQuitin/Nicabate/NicoDerm CQ
• Nicorette
• Nicotinell
• Zyban
• Tabex.
There, from 2013, you discover how high sales can go. Investigate opportunity. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.
You find geographical revenue predictions too.
National markets - where will highest revenues and growth occur?
In developed and developing countries, anti-smoking therapy will give opportunities to pharmaceutical companies. You see where and how, from 2013, understanding potential.
In our study you find individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries - Brazil, Russia, India, and China.
There you find countries with highest revenues and potential sales growth. Our work explains. You see the future of those products, appraising progress and discovering what it means, including emerging trends.
Issues affecting developers, producers, and sellers of anti-smoking medicines
The report explains forces affecting that industry and market from 2013, including these:
• Nicotine vaccines
• Monoamine oxidase inhibitors
• Cannabinoid receptor-1 antagonists
• Dopamine D3 antagonists
• Opiate antagonists
• Other smoking cessation aids in testing.
There you assess research and development (R&D), finding advances and outlooks for business. You also explore OTC switching and governmental support of medicines treating tobacco use, including their reimbursement. Discover what the present and future hold.
Companies and overall 2017 market value - how high can sales go?
From 2013, treatments for cigarette smoking hold potential for investments, medical advances, and higher revenues. Our work predicts the overall world market will reach $2.5bn in 2017, with further expansion to 2023.
That report shows you what technologies and organisations hold greatest potential. In particular, you explore these companies:
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Novartis.
Examine rising players, too, including Celtic Pharma, Selecta Biosciences, Aradigm, Extab Corporation, and Embera NeuroTherapeutics. Also, find interviews with three companies.
See what's possible in that industry. Our investigation explains the potential of its market, helping you stay ahead.
Information found nowhere else - discover the future of those neurological treatments
Through knowledge such as this, our new report helps you get recognition for insight:
• Revenues to 2023 at world level, with forecasting of 5 submarkets and 6 products - explore prospects for investments and sales
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - investigate countries for revenues and expected growth
• Prospects for companies - assess portfolios, results, R&D activities, and outlooks for future success.
Smoking Cessation Drugs: World Market Prospects 2013-2023 gives independent analysis. There you receive competitive intelligence found only in our work. That study helps you find the money and show your authority on those technologies and their potentials. Gain now.
Report Information
Publication date: 26/09/2013
Number of pages: 138
Pricing
Single User License:
Single user copies of this report are available for GBP1699
Departmental License:
Entitles up to 5 individual users to access the report for GBP2999 . This is not suitable for library usage.
Site License:
Allow your company to have access to this information at one location for GBP4999 . Suitable for library storage and use.
Global License:
Have your whole company worldwide to access this information for GBP6999 .
Ordering
All you need to do to order this report is contact Ana Tarazona on:
Telephone: +44 (0)207 549 9967 or email: ana -dot- tarazona (at) vgpharmaresearch.com
And provide the following information:
Report Title -
Report License - (Single User/Departmental/Site/Global)
Name -
Email -
Job Title -
Company -
Invoice Address -
Telephone and Fax number -
EEC VAT Number (only for E.U.)-
Table of Contents
1. Executive Summary
1.1 Smoking Cessation Drugs: World Market Overview
1.2 Aims and Format of the Report
1.3 Research and Analysis Methods
1.4 Scope of the Report
2. Introduction to Smoking Cessation
2.1 Tobacco- What is All the Fuss About?
2.1.1 How is Tobacco Consumed?
2.1.2 Tobacco Smoking is a Major Challenge for Healthcare Worldwide
2.2 Smoking Causes Many Health Disorders
2.3 Nicotine Addiction is at the Root of Smoking
2.4 Smoking Cessation
2.4.1 Why is it Difficult to Stop Smoking?
2.4.2 How Can Smokers Quit?
3. World Smoking Cessation Drugs Market, 2013-2023
3.1 How Will the Smoking Cessation Market Develop Until 2023?
3.2 Smoking Cessation Drugs Market by Type of Sale
3.2.1 Over-the-Counter (OTC) Smoking Cessation Drugs, 2012
3.2.1.1 OTC Smoking Cessation Drugs: Forecast, 2013-2023
3.2.2 Prescription (Rx) Smoking Cessation Drugs, 2012
3.2.2.1 Prescription Smoking Cessation Drugs: Forecast, 2013-2023
3.3 Smoking Cessation Drugs by Mechanism of Action
3.3.1 Nicotine Replacement Therapy
3.3.1.1 Nicotine Replacement Therapy, 2012
3.3.1.2 Nicotine Replacement Therapy Forecast, 2013-2023
3.3.2 Nicotine Receptor Partial Agonist Drugs
3.3.2.1 Nicotine Receptor Partial Agonist Drugs, 2012
3.3.2.2 Nicotine Receptor Partial Agonist Drugs Forecast, 2013-2023
3.3.3 Antidepressants
3.3.3.1 Antidepressants for Smoking Cessation, 2012
3.3.3.2 Antidepressants for Smoking Cessation: Forecast, 2013-2023
4. Leading National Markets for Smoking Cessation Drugs to 2023
4.1 Major Geographical Markets for the Smoking Cessation Industry in 2012
4.2 The US is Still the Market Leader
4.2.1 Smoking Prevalence Declining in the US
4.2.2 Availability and Reimbursement of Smoking Cessation Aids in the US
4.2.3 US Smoking Cessation Market Revenue, 2012
4.2.4 US Smoking Cessation Market Forecast, 2013-2023
4.2.5 Scope for US Smoking Cessation Market Expansion
4.3 The Japanese Smoking Cessation Market has Potential to Expand in Revenues
4.3.1 Japan has a Less Developed Smoking Cessation Market
4.3.2 The Japanese Smoking Cessation Market, 2012
4.3.3 Japanese Smoking Cessation Market Forecast, 2013-2023
4.4 The EU-5 Smoking Cessation Drugs Market
4.4.1 The UK Smoking Cessation Market
4.4.1.1 Tobacco Use in the UK
4.4.1.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailing of NRT
4.4.1.3 The UK has Strong Anti-Smoking Legislation
4.4.1.4 UK Smoking Cessation Market, 2012
4.4.1.5 UK Smoking Cessation Market Forecast, 2013-2023
4.4.2 The French Smoking Cessation Market
4.4.2.1 Tobacco Use in France is Still High
4.4.2.2 The French Smoking Cessation Market, 2012
4.4.2.3 French Smoking Cessation Market Forecast, 2013-2023
4.4.2.4 Factors Influencing the Development of the French Market
4.4.3 The Spanish Smoking Cessation Market
4.4.3.1 Tobacco Use in Spain is Low
4.4.3.2 The Spanish Smoking Cessation Market, 2012
4.4.3.3 The Spanish Smoking Cessation Market Forecast, 2013-2023
4.4.3.4 Spain's Anti-smoking Laws are Very Robust
4.4.4 The Italian Smoking Cessation Market
4.4.4.1 Reducing Tobacco Use in Italy is a Government Priority
4.4.4.2 The Italian Smoking Cessation Market, 2012
4.4.4.3 The Italian Smoking Cessation Market Forecast, 2013-2023
4.4.4.4 Italy has a Decades-Long Commitment to Reducing Smoking
4.4.5 The German Smoking Cessation Market
4.4.5.1 Germany is a Smoker's Citadel
4.4.5.2 The German Smoking Cessation Market, 2012
4.4.5.3 German Smoking Cessation Market Forecast, 2013-2023
4.4.5.4 Germany Has a Relaxed Attitude to Smoking
4.5 The BRIC Smoking Cessation Drugs Market is Untapped
4.5.1 The Brazilian Smoking Cessation Market
4.5.1.1 Tobacco Use in Brazil is Pervasive
4.5.1.2 The Brazilian Smoking Cessation Market, 2012
4.5.1.3 Brazilian Smoking Cessation Market Forecast, 2013-2023
4.5.1.4 Smoking Cessation Market Prospects in Brazil Look Bright
4.5.2 The Russian Smoking Cessation Market
4.5.2.1 Tobacco Use in Russia Forms a Serious Problem
4.5.2.2 The Russian Smoking Cessation Market, 2012
4.5.2.3 Russian Smoking Cessation Market Forecast, 2013-2023
4.5.2.4 The Russian Government has started to Take Positive Steps
4.5.3 The Indian Smoking Cessation Market: Vast Possibilities
4.5.3.1 India's Attitudes to Tobacco
4.5.3.2 The Indian Smoking Cessation Market, 2012
4.5.3.3 Indian Smoking Cessation Market Forecast, 2013-2023
4.5.3.4 Indian Smoking Cessation Market Still in its Infancy
4.5.3.5 Prospects for Growth of the Indian Smoking Cessation Market
4.5.4 The Chinese Smoking Cessation Market
4.5.4.1 Tobacco use in China is Unprecedented
4.5.4.2 The Chinese Smoking Cessation Market, 2012
4.5.4.3 Chinese Smoking Cessation Market Forecast, 2013-2023
4.5.4.4 The Chinese Smoking Cessation Market is Under Developed
4.5.4.5 China's Economic Progress Could be Hindered by Tobacco Use
5. Leading Smoking Cessation Products: Outlook to 2023
5.1 The Top 5 Brands Claimed Most of the Market in 2012
5.2 Nicotine Replacement Therapy is a Main Component of the Market
5.2.1 NiQuitin/Nicabate/NicoDerm CQ (GSK)
5.2.2 Nicorette (Johnson & Johnson/GSK)
5.2.3 Nicotinell (Novartis)
5.2.4 Other NRT Products
5.3 Champix/Chantix (Varenicline, Pfizer)
5.3.1 Champix/Chantix Sales Performance, 2012-2023
5.3.2 Champix/Chantix May Help in Treating Other Addictions
5.4 Zyban (Bupropion, GSK)
5.4.1 Zyban Sales Forecast, 2012-2023
5.5 Tabex - One to Watch Out For
5.6 Other Smoking Cessation Aids
5.6.1 Smokeless Tobacco
5.6.1.1 E-Cigarettes
5.6.1.2 Snus/Snuff
5.6.1.3 Gutkhas
5.6.2 CigRx Dietary Supplement
5.6.3 Dissolvable Tobacco
5.6.4 Behavioural Therapy
6. Smoking Cessation R&D Pipeline Analysis
6.1 Nicotine Vaccines: Hype or Hope?
6.1.1 TA-Nic (Celtic Pharma)
6.1.2 Niccine (Independent Pharmaceutica AB)
6.1.3 SEL-068 (Selecta Biosciences)
6.2 Monoamine Oxidase Inhibitors
6.3 Cannabinoid Receptor-1 Antagonists
6.4 Dopamine D3 Antagonists
6.5 Opiate Antagonists
6.6 ARD-1600 (Aradigm)
6.7 EMB-001(Embera NeuroTherapeutics)
6.8 Meclizine (Duke University/Philip Morris Products)
6.9 Other Smoking Cessation Aids Under Development
6.9.1 X22TM (22nd Century Group)
6.9.2 Other Developments
7. Smoking Cessation Industry: Qualitative Analyses, 2013-2023
7.1 The Smoking Cessation Market was Dominated by Four Companies, But for How Long?
7.2 SWOT and STEP Analysis of the Smoking Cessation Market
7.2.1 Strengths of the Smoking Cessation Industry
7.2.1.1 Innovation in Smoking Cessation Therapies
7.2.1.2 Innovative Marketing
7.2.1.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy
7.2.1.4 OTC Switching
7.2.1.5 Widespread Coverage of Smoking Cessation Products
7.2.2 Weaknesses of the Smoking Cessation Industry
7.2.2.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking
7.2.2.2 Currently-Marketed Smoking Cessation Therapies - Relapse Rate
7.2.2.3 Concerns Regarding the Development of Addiction to NRTs
7.2.3 Opportunities for the Smoking Cessation Industry
7.2.3.1 Smoking is Prevalent Worldwide and Slowly Increasing
7.2.3.2 Countries with Untapped Smoking Cessation Market Potential
7.2.3.3 Growth of Emerging-Economy Smoking Cessation Markets
7.2.3.4 Health Effects of Tobacco
7.2.3.5 Economic and Social Impact of Tobacco on Society
7.2.3.6 Framework Convention on Tobacco Control (FCTC)
7.2.3.7 Government-Sponsored Smoking Cessation Programmes
7.2.3.8 Increasing Tobacco Taxes
7.2.3.9 Smoking Bans
7.2.3.10 Warning Information on Tobacco Products
7.2.3.11 Bans on Tobacco Advertising, Promotion and Sponsorship
7.2.3.12 Upcoming Launch of Tabex
7.2.4 Threats to the Smoking Cessation Industry
7.2.4.1 Concern over Side-Effects of Smoking Cessation Drugs
7.2.4.2 Lack of Reimbursement for Smoking Cessation Therapies
7.2.4.3 Traditional Smokeless Tobacco
7.2.4.4 The E-Cigarette
8. Research Interviews
8.1 Interview with Dr Vladimir Kosev, Director Strategic Business Development, Sopharma
8.1.1 On Sopharma's Geographical Focus
8.1.2 On the Availability of Tabex
8.1.3 On the Efficacy of Tabex in Comparison to Other Products
8.1.4 On Any Other Points of Interest
8.2 Interview with Mr Rick Stewart, CEO, Extab Corporation
8.2.1 On Tabex's Release
8.2.2 On Tabex vs. Other Smoking Cessation Treatments
8.2.3 On the High Prices of Smoking Cessation Products Reducing Revenues in Poorer Nations
8.2.4 On the Future Direction of the Industry
8.2.5 On Any Other Points of Interest
8.3 Interview with Mr Trevor Van Meirlo, CEO, Evolution Health Systems
8.3.1 Unmet Needs
8.3.2 Major Areas of Focus
8.3.3 Smoking Cessation R&D Pipeline
8.3.4 Opportunities for Revenue Growth
8.3.5 Market Drivers
8.4 Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, University of London
8.4.1 Unmet Needs
8.4.2 Major Areas of Focus and R&D Pipeline
8.4.3 Opportunities for Revenue Growth
8.4.4 Market Drivers
9. Conclusions of the Study
9.1 Smoking is the Main Cause of Preventable Deaths Worldwide
9.2 Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2013 to 2023
9.3 World Smoking Cessation Market: Prospects to 2023
9.4 Market Drivers
9.5 Leading and Emerging Smoking Cessation Markets
9.6 Concluding Remarks
List of Tables
Table 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023
Table 3.2 World Smoking Cessation Market Drivers and Restraints, 2012-2023
Table 3.3 Smoking Cessation Drug Market Forecast ($m) by Type of Sales, 2012-2023
Table 3.4 Over-The-Counter Smoking Cessation Market Forecast ($m), 2012-2023
Table 3.5 OTC Smoking Cessation Market Drivers and Restraints, 2012-2023
Table 3.6 Prescription (Rx) Smoking Cessation Market Forecast ($m), 2012-2023
Table 3.7 Prescription Smoking Cessation Drivers and Restraints, 2012-2023
Table 3.8 Smoking Cessation Market Forecasts by Drug Type ($m), 2012-2023
Table 3.9 Nicotine Replacement Therapy Market Forecast ($m), 2012-2023
Table 3.10 Nicotine Replacement Therapy Drivers and Restraints, 2012-2023
Table 3.11 NRPA Market Forecast ($m), 2012-2023
Table 3.12 NRPA Drivers and Restraints, 2012-2023
Table 3.13 Antidepressants Market Forecast ($m), 2012-2023
Table 3.14 Antidepressants Market Drivers and Restraints, 2012-2023
Table 4.1 Smoking Cessation Drugs Market Forecast ($m) by Leading Countries, 2012-2023
Table 4.2 Smoking Cessation Drugs Market Forecast ($m) & Market Shares (%) by Leading Countries, 2012
Table 4.3 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Table 4.4 US Smoking Cessation Market Drivers and Restraints, 2012-2023
Table 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Table 4.6 Japanese Smoking Market Cessation Drugs Drivers and Restraints, 2012-2023
Table 4.7 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023
Table 4.8 EU-5 Smoking Cessation Market Drivers and Restraints, 2012-2023
Table 4.9 UK Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.10 French Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.11 Spanish Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.12 Italian Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.13 German Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.14 BRIC Smoking Cessation Market Forecasts ($m), 2012-2023
Table 4.15 BRIC Smoking Cessation Drugs Drivers and Restraints, 2012-2023
Table 4.16 Brazilian Smoking Cessation Market Forecasts ($m), 2012-2023
Table 4.17 Russian Smoking Cessation Market Forecasts ($m), 2012-2023
Table 4.18 Indian Smoking Cessation Market Forecast ($m), 2012-2023
Table 4.19 Chinese Smoking Cessation Market Forecast ($m), 2012-2023
Table 5.1 Top 5 Smoking Cessation Drugs' Sales ($m) and Market Shares (%), 2012
Table 5.2 Leading Smoking Cessation Brands: Sales Forecasts ($m), 2012-2023
Table 5.3 Nicotine Replacement Therapy Types, 2012
Table 5.4 NiQuitin /Nicabate/NicoDerm CQ NRT Brands, 2012
Table 5.5 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023
Table 5.6 NiQuitin/Nicabate/NicoDerm CQ Drivers and Restraints, 2012-2023
Table 5.7 Nicorette NRT Brands, 2012
Table 5.8 Nicorette Sales Forecast ($m), 2012-2023
Table 5.9 Nicorette Drivers and Restraints, 2012-2023
Table 5.10 Nicotinell Sales Forecast ($m), 2012-2023
Table 5.11 Nicotinell Drivers and Restraints, 2012-2023
Table 5.12 Champix/Chantix Sales Forecast ($m), 2012-2023
Table 5.13 Champix/Chantix Drivers and Restraints, 2012-2023
Table 5.14 Zyban Sales Forecast ($m), 2012-2023
Table 5.15 Zyban Drivers and Restraints 2012-2023
Table 5.16 Tabex Sales Forecast ($m), 2012-2023
Table 5.17 Tabex Drivers and Restraints, 2012-2023
Table 6.1 Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2013
Table 6.2 Smoking Cessation R&D Pipeline: Apparent Disappointments
Table 7.1 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and Market Share (%), 2012
Table 7.2 Leading Companies in the Smoking Cessation Drugs Market, by Revenues ($m) and Market Share (%), 2023
Table 7.3 Other Companies Operating in the Smoking Cessation Industry
Table 7.4 SWOT Analysis of the Industry and Market, 2012-2023
Table 7.5 STEP Analysis of the Industry and Market, 2012-2023
Table 9.1 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by OTC and Rx, 2013, 2017 & 2023
Table 9.2 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Drug Type, 2013, 2017 & 2023
Table 9.3 Smoking Cessation Drug Market Forecast ($m) and Market Shares (%) by Leading Countries, 2013, 2017 & 2023
List of Figures
Figure 2.1 Smoking-Related Health Disorders
Figure 3.1 World Smoking Cessation Market Forecast ($m), 2012-2023
Figure 3.2 Smoking Cessation Market Shares (%) by Type of Sale, 2012
Figure 3.3 OTC Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Figure 3.4 Rx Smoking Cessation Market Forecast ($m), 2012-2023
Figure 3.5 Smoking Cessation Market Shares (%) by Drug Type, 2012
Figure 3.6 NRT Market Forecast ($m), 2012-2023
Figure 3.7 NRPA Market Forecast ($m), 2012-2023
Figure 3.8 Antidepressants for Smoking Cessation: Market Forecast ($m), 2012-2023
Figure 4.1 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2012
Figure 4.2 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2017
Figure 4.3 Smoking Cessation Drugs Market Shares (%) by Leading Countries, 2023
Figure 4.4 US Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Figure 4.5 Japanese Smoking Cessation Drugs Market Forecast ($m), 2012-2023
Figure 4.6 EU5 Smoking Cessation Market Forecasts ($m), 2012-2023
Figure 4.7 UK Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.8 French Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.9 Spanish Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.10 Italian Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.11 German Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.12 BRIC Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.13 Brazilian Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.14 Russian Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.15 Indian Smoking Cessation Market Forecast ($m), 2012-2023
Figure 4.16 Chinese Smoking Cessation Market Forecast ($m), 2012-2023
Figure 5.1 Top 5 Smoking Cessation Drugs: Market Shares (%), 2012
Figure 5.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($m), 2012-2023
Figure 5.3 Nicorette Sales Forecast ($m), 2012-2023
Figure 5.4 Nicotinell Sales Forecast ($m), 2012-2023
Figure 5.5 Champix/Chantix Sales Forecast ($m), 2012-2023
Figure 5.6 Zyban Sales Forecast ($m), 2012-2023
Figure 5.7 Tabex Sales Forecast ($m), 2012-2023
Figure 7.1 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2012
Figure 7.2 Leading Companies in the Smoking Cessation Drugs Industry by Market Share (%), 2023
Figure 9.1 Smoking Cessation Drugs: World Market Revenue Forecast ($m), 2012-2023
Figure 9.2 Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2013, 2017 & 2023
Companies Mentioned in this report
22nd Century Group
Action on Smoking on Health (ASH)
Advent Life Sciences
Alkermes
American Heart Association (AHA)
American Lung Association (ALA)
Aradigm
Australian Therapeutic Goods Administration
BGP Group
Boots
Cochrane Collaboration
Cambrex
Campaign for Tobacco-Free Kids
Cancer Centre and Institute of Oncology
Ceejay Healthcare
Celtic Pharma
Centers for Disease Control and Prevention (CDC)
Cephalon
China National Tobacco Corporation
CN Creative
Cytos Biotechnology
Duke University
Embera NeuroTherapeutics
European Medicines Agency (EMA)
Evolution Health Systems
Evotec
Excelsa Pharma
Extab Corporation
Fertin Pharma A/S
Food and Drug Administration (US FDA)
GlaxoSmithKline (GSK)
Haihang Industry Company
Health Canada
Independent Pharmaceutica AB
Japanese Ministry of Health, Labour and Welfare (MHLW)
Japan Tobacco
Johnson & Johnson
Karolinska Institutet
LEO Pharma
LSU Health Sciences Center - Shreveport
Mayo Clinic
Medicines and Healthcare Products Regulatory Agency (MHRA)
Nabi Biopharmaceuticals
National Cancer Institute (NCI)
National Health Service (UK NHS)
National Institute for Health and Clinical Excellence (UK NICE)
National Institute on Drug Abuse (NIDA)
Next Safety
Nicobrand
Niconovum AB
Nicoventures
Novartis
Nulife
Nu-Mark
Perrigo
Pfizer
Philip Morris Products S.A
Queen Mary University of London
Revolymer
R.J. Reynolds Tobacco Company
Rock Creek Pharmaceuticals
Roche
Ruyan
Sanofi
Selecta Biosciences
Sopharma
Spanish Ministry of Health, Social Services and Equality
Star Scientific
Taj Pharmaceuticals
Target Corporation
Teva Pharmaceutical Industries
Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry
Tobacco Manufacturers Association
University College London (UCL)
UK Centre for Tobacco Control Studies
Walmart
Wolfson Institute of Preventive Medicine
World Bank
World Health Organization (WHO)
Zenara
Pricing
Single User License:
Single user copies of this report are available for GBP1699
Departmental License:
Entitles up to 5 individual users to access the report for GBP2999 . This is not suitable for library usage.
Site License:
Allow your company to have access to this information at one location for GBP4999 . Suitable for library storage and use.
Global License:
Have your whole company worldwide to access this information for GBP6999 .
Ordering
All you need to do to order this report is contact Ana Tarazona on:
Telephone: +44 (0)207 549 9967 or email: ana -dot- tarazona (at) vgpharmaresearch.com
And provide the following information:
Report Title -
Report License - (Single User/Departmental/Site/Global)
Name -
Email -
Job Title -
Company -
Invoice Address -
Telephone and Fax number -
EEC VAT Number (only for E.U.)-
Please feel free to contact me should you have any questions, or wish to purchase a copy, I look forward to hearing from you.
Best Regards,
Ana Tarazona
Last edited:
